These genes included TP53 binding protein, TP53BP2 (14); proto-oncogene, MYC (4); Wnt regulator, CTNNB1 (10); PI3K pathway component, PIK3AP1 (1); MAPK/ERK pathway kinase, BRAF (5); and tumor suppressors, CDK2A, CDK2B, and CDK2C (36), all of which are known to be mutated in the HepG2 cancer cells. This evidence concerns the gene TP53BP2 and cancer.